Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC

Advanced/Metastatic Colorectal Cancer Clinical Trial

Official title: An Open, Single-arm, Phase II Clinical Study Evaluating the Safety and Initial Efficacy of LTC004 in Combination With Regorafenib in the Treatment of Metastatic Colorectal Cancer

Status Not yet recruiting

Clinical Trial Summary

This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in combination with regorafenib in patients with mCRC. A safety introductory trial was conducted to receive LTC004 in combination with regorafenib before starting the formal trial. After completing a 28-day safety assessment, safety will be confirmed before entering the formal trial phase. Further evaluation of the safety and efficacy of LTC004 in combination with regorafenib in the treatment of mCRC

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Advanced/Metastatic Colorectal Cancer
• Colorectal Neoplasms

• NCT number: NCT06322563
• Study type: Interventional
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Ting Deng
• Phone: 15802243063
• Email: 18526812877@163.com
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 1, 2024
• Completion date: March 1, 2025